The MARCH Trial Dismantles a Decades-Old Ritual in Intensive Care

A Routine Gesture Called Into Question

In nearly every hospital on earth, a routine gesture has become so common that nobody questions it anymore: giving mucoactive agents to patients on a ventilator to help clear the mucus clogging their airways. According to data reported by Medical Xpress on July 2, 2026, more than 80% of intensive care units worldwide use these drugs, given to roughly one in four or five ventilated patients.

But a massive British clinical trial named MARCH, published in the prestigious New England Journal of Medicine, is now shaking up this near-universal practice. The findings, as rigorous as they are troubling, suggest this routine gesture might not only be useless, but potentially dangerous for some of the most vulnerable patients in the healthcare system.

The Profile of a Crumbling Medical Certainty

This piece profiles this major scientific reckoning: how a treatment used for decades, based on clinical observation rather than robust evidence, suddenly finds itself under the microscope of evidence-based medicine, with potential consequences for millions of patients in intensive care every year.

The MARCH trial, whose full name is Mucoactives in Acute Respiratory Failure: Carbocisteine and Hypertonic Saline, enrolled nearly 2,000 adults across 71 hospitals in the United Kingdom, a colossal effort to answer a question as simple as it was neglected: do these drugs actually help?

A Rigorous Four-Arm Methodology

The MARCH trial was designed as a two-by-two factorial design, a sophisticated statistical methodology that allows two distinct treatments to be tested simultaneously within the same patient population. Participants, aged 16 or older, were split into four groups: those receiving carbocisteine alone, those receiving hypertonic saline solution alone, those receiving both treatments combined, and those receiving neither.

This approach allowed the researchers, led notably by researcher Bronwen Connolly, to precisely isolate each drug's effect while maximizing the study's statistical power thanks to a critically ill patient population unusually large for this kind of intensive care research.

Close Follow-Up for Up to 28 Days

The researchers tracked patients for up to 28 days, or until they could breathe without mechanical assistance, a long enough observation window to capture the clinically significant effects of the treatments tested in this severely ill patient population.

The study, conducted in open-label fashion, means doctors and researchers knew which treatment each patient was receiving, a recognized but common methodological limitation in this type of pragmatic trial conducted directly at the bedside under real clinical conditions.

No Difference in Ventilation Duration

The study's central finding is unambiguous: neither carbocisteine nor hypertonic saline solution reduced the time patients spent on a ventilator compared with standard care. Patients across every group regained independent breathing after a similar period, generally between seven and eight days, regardless of which mucoactive treatment they received.

This result directly contradicts the clinical hypothesis that justified the routine use of these drugs for decades: the idea that mechanically clearing the airways would speed up recovery and weaning from the ventilator in patients with acute respiratory failure.

No Gain in Survival or Length of Hospital Stay

Beyond ventilation duration, the trial found no significant improvement in survival, nor in other major clinical measures such as length of stay in the intensive care unit or in hospital overall, reinforcing the idea that these treatments simply don't deliver the long-assumed benefits.

For clinicians who have prescribed these drugs almost by reflex since the start of their careers, these results represent a scientific shock that's hard to ignore, calling into question practices taught and passed down from generation to generation in intensive care units around the world.

Unexpected Gastrointestinal Bleeding

The real shock of this study may lie in the documented side effects. Patients treated with carbocisteine showed roughly a sevenfold higher risk of gastrointestinal bleeding compared with patients who did not receive this treatment, with a rate of 1.4% versus just 0.2% in the comparison group.

This kind of bleeding, potentially serious in patients already weakened by acute respiratory failure, adds a layer of clinical complexity to a population of patients for whom every additional complication can have disproportionate consequences for overall prognosis.

A Saline Solution That Tightens the Airways

Meanwhile, hypertonic saline solution was linked to airway tightening, a phenomenon called bronchoconstriction, sometimes requiring urgent rescue medication to restore adequate breathing in patients affected by this adverse effect.

Researchers also found an increased frequency of dangerous drops in blood oxygen levels during treatment administration, a particularly worrying effect in patients whose respiratory function is already severely compromised by their critical condition.

Clinical Observation Rather Than Rigorous Proof

How can such a widespread practice have survived so long without solid scientific evidence? The answer lies largely in the history of intensive care medicine itself, where many treatments became standard through clinical observation and accumulated experience rather than rigorous randomized trials like the one conducted under MARCH.

Doctors, facing patients in acute respiratory distress, long favored an intuitive logic: if mucus is blocking the airways, clearing it mechanically or chemically should logically improve the situation. That logic, reasonable as it seemed, wasn't confirmed by the data from this large-scale trial.

A Scientific Uncertainty Long Ignored

Before MARCH was published, the available evidence on the effectiveness and safety of these mucoactive agents remained insufficient, particularly regarding their routine use in critically ill patients on mechanical ventilation in high-intensity intensive care settings.

This scientific blind spot, long tolerated by the international medical community, illustrates a broader challenge in modern medicine: the difficulty of questioning established practices, even when the evidence supporting them remains weak or nonexistent.

Patients Among the Most Vulnerable in the Healthcare System

Behind every number in this study is a human being in acute respiratory distress, often unconscious or sedated, entirely dependent on a machine to breathe and on the clinical judgment of their care team to guide treatment during the most critical moments of their life.

These patients, among the most vulnerable in the entire hospital system, generally have no say in the treatment decisions made at their bedside, which makes it all the more crucial that these decisions rest on solid scientific evidence rather than unverified habits.

Families Facing Medical Uncertainty

For the families of intensive care patients, learning that a treatment given to a loved one might not work, or could even cause harm, raises legitimate and sometimes painful questions about the quality of care received during the most vulnerable moments of their lives.

These scientific revelations, though necessary to improve future medicine, can also generate understandable anxiety among relatives of patients who already received these mucoactive treatments before these now well-documented results were published.

A Likely Revision of Standard Practices

Faced with results this robust, published in a journal as prestigious as the New England Journal of Medicine, many intensive care experts anticipate a gradual revision of the standard protocols governing mucoactive agent use in critical care units worldwide.

This revision likely won't happen overnight, since clinical habits entrenched for decades generally take time to change, even in the face of solid scientific evidence like that provided by the MARCH trial published in early July 2026.

A Warning Sign for Other Unverified Practices

Beyond the specific case of mucoactive agents, this study sends a broader warning about other routine medical practices that may never have been subjected to this level of rigorous scrutiny, a major issue for the overall credibility of evidence-based medicine.

Intensive care professional societies will likely need to quickly examine these results in order to issue new official clinical recommendations, a process that could take several months before it translates concretely into hospitals worldwide.

A Reception Marked by Surprise and Methodological Respect

The publication of the MARCH trial drew considerable attention within the international scientific community, with several intensive care medicine experts praising both the study's methodological rigor and the clinical importance of its conclusions for daily critical care practice.

Specialized outlets like Medical Xpress, News-Medical, and EurekAlert widely relayed these findings as soon as they were published in early July 2026, contributing to rapid dissemination of the information across the global medical community and the general public interested in these health issues.

Calls for More Similar Research

Several researchers used this opportunity to call for more rigorous clinical trials on other common intensive care practices, noting that critical care paradoxically remains one of the least-studied fields when it comes to large-scale randomized trials, despite its vital importance.

This collective reflection could, over time, transform the scientific culture of intensive care units, encouraging more systematic evaluation of treatments administered daily to millions of critical patients worldwide every year.

A Dilemma Between Habit and New Evidence

For doctors and nurses working daily in intensive care, these results create an immediate practical dilemma: keep administering treatments whose usefulness has just been seriously called into question, or quickly change their clinical practices while awaiting more formal official guidance from professional societies.

This dilemma illustrates a permanent tension in modern medicine between the need to act quickly at the patient's bedside and the often much longer time science takes to produce, publish, and integrate robust evidence into daily clinical protocols.

Continuing Education as the Key to Transition

Experts agree on the importance of rigorous continuing education to guide clinicians through this transition, so that deeply entrenched habits don't simply persist out of professional inertia rather than an informed choice grounded in the most recent data.

This training will likely need to include an in-depth discussion of the MARCH trial's results, along with a broader reflection on how intensive care units integrate, or fail to integrate quickly enough, newly available scientific evidence into their clinical practice.

A Geographic Context and an Open-Label Design to Consider

Like any scientific study, the MARCH trial has certain methodological limitations that deserve honest acknowledgment. Conducted exclusively in the United Kingdom, the study may not perfectly reflect the practices and patient populations of other regions of the world with different healthcare systems.

In addition, the trial's open-label design, in which doctors and researchers knew which treatment was being given, introduces a recognized methodological limitation, though a common and generally accepted one in this type of pragmatic clinical research conducted directly in a real hospital setting.

Questions That Remain Open for Future Research

This study also doesn't answer every possible question, notably whether certain specific subgroups of patients might still benefit from these mucoactive treatments under particular clinical circumstances not covered by this trial.

The researchers themselves acknowledge the need to continue investigating in order to refine understanding of these treatments, rather than simply abandoning them wholesale based solely on these results, robust as they are for the general population studied.

A Global Public Health Issue

Though conducted in the United Kingdom, this study has direct implications for healthcare systems worldwide, given that the use of mucoactive agents in intensive care is a nearly universal practice, potentially affecting millions of patients every year on every continent.

North American, European, and Asian hospitals will likely closely follow how clinical recommendations evolve as a result of this study, in a context where international standardization of intensive care practices remains a shared goal of the global medical community.

An Opportunity for the West to Lead by Scientific Example

This study also illustrates the Western medical research system's capacity for self-criticism and for producing rigorous evidence even when it contradicts long-established practices, a scientific and institutional strength few other regions of the world can claim with the same transparency.

This capacity for scientific self-criticism remains a considerable asset for the West in the global competition for medical excellence, at a time when other world powers are investing massively in their own health research capabilities.

A Reminder of the Importance of Randomized Trials

The MARCH trial is a powerful reminder of the fundamental importance of large-scale randomized clinical trials for validating, or invalidating, medical practices long established on the sole basis of accumulated clinical experience without rigorous scientific validation.

This type of research, though costly and demanding in terms of human and financial resources, remains indispensable to ensuring that treatments given to patients rest on solid evidence rather than on scientifically unverified medical traditions.

A Model to Replicate for Other Established Practices

Several experts hope this study will serve as a model for other similar research aimed at rigorously evaluating other common intensive care practices, a field where many therapeutic interventions have never been subjected to this level of rigorous scientific scrutiny.

This methodical approach, if it becomes more widespread, could gradually transform the scientific culture of intensive care medicine worldwide, ultimately benefiting the most vulnerable patients in our contemporary healthcare systems.

Informed Consent in the Face of Scientific Uncertainty

This study also raises important ethical questions about the informed consent of patients and their families regarding treatments whose effectiveness and safety had never been fully established by rigorous scientific evidence before these results were published.

How can patients and their loved ones be adequately informed about treatments given in an emergency situation, when the medical community itself was, until recently, unaware of their true efficacy and risk profile in a critical intensive care setting?

The Collective Responsibility of the Medical Community

These ethical questions point to a broader collective responsibility for the international medical community: to continually question its own established practices, even the most routine ones, to ensure that every treatment administered rests on the best scientific evidence available at any given time.

This responsibility, demanding as it is, remains at the very heart of modern medicine's mission, which must constantly evolve as new scientific evidence, like that provided by the MARCH trial, challenges certainties long taken for granted.

Don't Panic, but Stay Informed

For the general public and families of patients who have spent time in intensive care, it's important to keep these results in perspective: this study doesn't mean every treatment received was dangerous or useless, but rather that one specific practice now deserves review in light of solid new scientific evidence.

Patients and families with questions about treatments received in the past should discuss them directly with their treating medical team, rather than drawing hasty conclusions from media coverage, however well-documented it may be on the subject.

An Example of Scientific Transparency Worth Applauding

This study also positively illustrates the medical system's capacity to publicly release information that challenges its own practices, an exercise in transparency rarely highlighted but essential to public trust in modern medicine.

This scientific transparency, uncomfortable as it may be for some healthcare professionals, ultimately benefits the entire healthcare system and future patients who will benefit from more scientifically validated clinical practices.

A Result That Must Change Practices, Not Just Minds

The MARCH trial will likely go down in the annals of intensive care medicine as a striking example of how a practice this widespread and this established can collapse in the face of rigorous scientific evidence, produced through exemplary methodology and a patient population large enough to dispel any reasonable doubt.

This result must not simply fuel academic discussions in specialized journals, but must translate concretely into the clinical protocols of intensive care units worldwide, for the direct benefit of the millions of patients treated there every year for potentially fatal acute respiratory distress.

A Permanent Invitation to Question Our Medical Certainties

More broadly, this study reminds us of an essential lesson in humility: no medical practice, however old and widespread, should ever be shielded from rigorous scientific scrutiny, particularly when human lives directly depend on the real effectiveness of these daily therapeutic interventions.

This invitation to permanent scientific humility, uncomfortable as it may be for a medical profession accustomed to its certainties, is likely the true lasting legacy of this British clinical trial that will have marked intensive care medicine in 2026.

By Maxime Marquette, columnist

Editorial stance

I am not a journalist but a columnist and analyst. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. I claim analytical clarity, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

Method and sources

This text keeps the basic distinction between verified facts and interpretive analysis. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under Sources, never here.

Primary source families used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

Secondary source families: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under Sources.

Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a critical, contextual synthesis based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.